Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Gilead Sciences Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Gilead Sciences Inc., consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income
Depreciation expense
Amortization expense
Stock-based compensation expense
Deferred income taxes
Net loss from equity securities
Acquired in-process research and development expenses
In-process research and development impairment
Other
Accounts receivable, net
Inventories
Prepaid expenses and other
Accounts payable
Income tax assets and liabilities, net
Accrued and other liabilities
Changes in operating assets and liabilities
Adjustments to reconcile net income to net cash provided by operating activities
Net cash provided by operating activities
Purchases of marketable debt securities
Proceeds from sales of marketable debt securities
Proceeds from maturities of marketable debt securities
Acquisitions, including in-process research and development, net of cash acquired
Purchases of equity securities
Capital expenditures
Other
Net cash used in investing activities
Proceeds from debt financing, net of issuance costs
Proceeds from issuances of common stock
Repurchases of common stock under repurchase programs
Repayments of debt and other obligations
Payments of dividends
Other
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Gilead Sciences Inc. net cash provided by operating activities decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Gilead Sciences Inc. net cash used in investing activities increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Gilead Sciences Inc. net cash provided by (used in) financing activities increased from 2022 to 2023 and from 2023 to 2024.